Clinical data | |
---|---|
Trade names | Azaribine |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.016.832 |
Chemical and physical data | |
Formula | C14H17N3O9 |
Molar mass | 371.302 g·mol−1 |
3D model ( JSmol) | |
| |
|
Azaribine (triacetyl-6-azauridine) is a drug which was developed for the treatment of psoriasis, [1] and also has anti-cancer and antiviral actions. [2] [3] It is a prodrug which is metabolised to the nucleoside analogue 6-azauridine in the body. Azaribine was approved for clinical use in treatment of psoriasis, [4] but subsequently withdrawn because of toxicity issues, [5] [6] however it continues to be researched as a potential agent for the treatment of emerging viral diseases. [7]
Clinical data | |
---|---|
Trade names | Azaribine |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.016.832 |
Chemical and physical data | |
Formula | C14H17N3O9 |
Molar mass | 371.302 g·mol−1 |
3D model ( JSmol) | |
| |
|
Azaribine (triacetyl-6-azauridine) is a drug which was developed for the treatment of psoriasis, [1] and also has anti-cancer and antiviral actions. [2] [3] It is a prodrug which is metabolised to the nucleoside analogue 6-azauridine in the body. Azaribine was approved for clinical use in treatment of psoriasis, [4] but subsequently withdrawn because of toxicity issues, [5] [6] however it continues to be researched as a potential agent for the treatment of emerging viral diseases. [7]